Karen Chagin, M.D.
About Karen Chagin, M.D.
Karen Chagin, M.D., is the SVP of Early-Stage Development with a robust background in pediatric hematology and oncology, and extensive experience in pharmaceutical development.
Karen Chagin, M.D. Education Background
Karen Chagin, M.D., holds a Bachelor of Arts degree from the University of Pennsylvania. She further pursued her medical education at the Temple University School of Medicine, where she earned her M.D. Following her medical degree, Dr. Chagin completed her residency at Children's Memorial Hospital in Chicago. To specialize in pediatric hematology and oncology, she undertook a fellowship at The Children's Hospital of Philadelphia.
Karen Chagin, M.D. Early-Stage Development Expertise
Karen Chagin, M.D., currently serves as the Senior Vice President of Early-Stage Development. In this role, Dr. Chagin leverages her extensive medical education and experience in the pharmaceutical industry to oversee the development of early-stage biopharmaceutical projects. Her background in pediatric hematology and oncology, coupled with her experience in early-stage development, positions her as a key contributor to innovative medical treatments.
Karen Chagin, M.D. Career in the Pharmaceutical Industry
Karen Chagin, M.D., began her career in the pharmaceutical industry in 2009 at GlaxoSmithKline (GSK). At GSK, she served as a Safety Development leader and Medical Director for Promacta/Revolade. Her role involved contributions to the global registration of several products and indications. Following her tenure at GSK, Dr. Chagin held various substantial roles, furthering her expertise and impact in the pharmaceutical sector.
Karen Chagin, M.D. Leadership Roles
Karen Chagin, M.D., has held numerous leadership positions throughout her career. She previously served as the Chief Medical Officer at Tmunity, where she contributed to significant organizational achievements. After Tmunity's acquisition by Kite, she became the Head of Kite Philadelphia. Moreover, her role as a Scientific Director in Oncology Early Development at Janssen showcases her depth of experience in guiding early-stage medical research and development.
Karen Chagin, M.D. Contributions to Oncology
Karen Chagin, M.D., has made substantial contributions to the field of oncology, particularly through her roles in early-stage development and leadership positions. Her career includes significant stints at reputable institutions such as Janssen, Tmunity, and Children's hospitals. These roles have allowed Dr. Chagin to influence the development and registration of multiple oncology-related products and treatments, underlining her impact on the medical and pharmaceutical community.